GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bioage Labs Inc (NAS:BIOA) » Definitions » Debt-to-Revenue

BIOA (Bioage Labs) Debt-to-Revenue : N/A (As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Bioage Labs Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Bioage Labs's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $6.27 Mil. Bioage Labs's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $3.94 Mil. Bioage Labs's annualized Revenue for the quarter that ended in Sep. 2024 was $0.00 Mil.

Bioage Labs Debt-to-Revenue Historical Data

The historical data trend for Bioage Labs's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioage Labs Debt-to-Revenue Chart

Bioage Labs Annual Data
Trend Dec22 Dec23
Debt-to-Revenue
N/A N/A

Bioage Labs Quarterly Data
Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Debt-to-Revenue Get a 7-Day Free Trial N/A N/A N/A N/A N/A

Competitive Comparison of Bioage Labs's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Bioage Labs's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bioage Labs's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bioage Labs's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Bioage Labs's Debt-to-Revenue falls into.


Bioage Labs Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Bioage Labs's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(45.051 + 8.201) / N/A
=N/A

Bioage Labs's annualized Debt-to-Revenue for the quarter that ended in Sep. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(6.273 + 3.94) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Sep. 2024) Revenue data.

Bioage Labs Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Bioage Labs's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Bioage Labs Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bioage Labs Inc (NAS:BIOA) » Definitions » Debt-to-Revenue
Comparable Companies
Traded in Other Exchanges
N/A
Address
1445A South 50th Street, Richmond, CA, USA, 94804
Website
https://www.bioagelabs.com
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. Its Products are Azelaprag (BGE-105), an apelin receptor APJ agonist that increases weight loss and improves body composition combined with incretin drugs. and BGE-100 is targeting metabolic diseases and neuroinflammation.